Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Solid Biosciences Inc.

Get SEC filing alerts via email and in your feed for Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

About Solid Biosciences Inc.

Solid Biosciences Inc. is a life sciences company developing gene therapies for rare neuromuscular and cardiac diseases. Its core focus includes Duchenne muscular dystrophy, Friedreich's ataxia, and inherited cardiac conditions, utilizing AAV-based gene transfer technology. The company advances innovative platform technologies, proprietary capsids, and strategic collaborations to deliver transformative treatments aimed at addressing unmet medical needs in underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Solid Biosciences Inc.

1
1
Solid Biosciences Inc. Solid Biosciences Reports $56.7 Million Net Loss in Q1 2026, Driven by Increased R&D Expenses

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Solid Biosciences Inc. Solid Biosciences Reports $174.3 Million Net Loss for 2025, Increases R&D Spending

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Solid Biosciences Inc. Solid Biosciences Reports $45.8 Million Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Solid Biosciences Inc. Solid Biosciences Reports Increased Losses and Improved Financial Position in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Solid Biosciences Inc. Solid Biosciences Reports $39.3 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Solid Biosciences Inc. Solid Biosciences Reports $124.7 Million Net Loss for 2024, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Solid Biosciences Inc. Solid Biosciences Reports Financial Results for Q3 2024, Completes Private Placement and Advances Gene Therapy Pipeline

Via official filing (AI summary) | over 1 year ago | 0 comments